<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78061">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089269</url>
  </required_header>
  <id_info>
    <org_study_id>iOM-01281</org_study_id>
    <secondary_id>Tumorregister Pankreaskarzinom</secondary_id>
    <nct_id>NCT02089269</nct_id>
  </id_info>
  <brief_title>Tumor Registry Pancreatic Cancer</brief_title>
  <acronym>TPK</acronym>
  <official_title>Clinical Registry on Treatment Reality and Therapy Sequences in Patients With Metastatic or Locally Advanced Pancreatic Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The registry aims to collect and analyse information on the antineoplastic treatment of
      metastatic or locally advanced pancreatic cancer in daily routine practice in Germany. The
      registry will follow up patients for two years. It will identify common sequences of
      treatments used as well as changes in the treatment of the disease. Health-related quality
      of life will be analysed during the course of the treatment (PanLife). Based on the
      available data a prognostic score will be developed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment reality in Germany</measure>
    <time_frame>over 5 years</time_frame>
    <description>description of treatments selected for patients per line of therapy over the course of the project</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1250</enrollment>
  <condition>Pancreas Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pancreatic cancer undergoing antineoplastic treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic or locally advanced pancreatic cancer

          -  18 years and older

          -  Antineoplastic treatment

          -  Date of consent no later than 2 weeks after start of first-line treatment

        Exclusion Criteria:

          -  No pancreatic cancer

          -  Below 18 years and older

          -  No antineoplastic treatment

          -  Date of consent later than 2 weeks after start of first-line treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanna Hegewisch-Becker, Prof. MD</last_name>
    <role>Study Chair</role>
    <affiliation>Outpatient Clinic, Hamburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hofheinz Ralf, Prof. MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Clinic, Mannheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Hamm, Dr.</last_name>
    <phone>+4976115242-0</phone>
    <email>info@iomedico.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>iOMEDICO</name>
      <address>
        <city>Freiburg</city>
        <state>BW</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 20, 2017</lastchanged_date>
  <firstreceived_date>March 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic neoplasms</keyword>
  <keyword>neoplasms</keyword>
  <keyword>registry</keyword>
  <keyword>advanced pancreatic cancer</keyword>
  <keyword>health services research</keyword>
  <keyword>epidemiology</keyword>
  <keyword>Germany</keyword>
  <keyword>palliative treatment</keyword>
  <keyword>palliative care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
